Investor Relations

(Security Code :4506 TSE Prime)

Pick Up

Sep. 02, 2026	Sumitomo Pharma Announces Personnel Changes	Corporate
Aug. 31, 2026	Sumitomo Pharma Selected as a Constituent of Five GPIF-Adopted ESG Indexes	Sustainability
Aug. 28, 2026	Notice Concerning Gain on Return of Retirement Benefit Trust (Extraordinary Income) Recorded in the Company’s Non-Consolidated Financial Statements (Japanese GAAP)	Finances
Aug. 26, 2026	Sumitomo Pharma Selected as a Constituent of the JPX Prime 150 Index	Others
Aug. 13, 2026	Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa（PDF/137KB）	R&D
Aug. 12, 2026	Regarding a Report Concerning Sumitomo Pharma (The Company's Views on “Sumitomo Chemical and Sumitomo Pharmaceutical: Part II - CiRA, Dr. Yamanaka, and the undisclosed history of image duplication concerns”)	Others

Oct. 30, 2026	2nd Quarter of FY2026 financial results announcement (scheduled to be disclosed at 3:30 p.m.), conference on 2nd quarter FY2026 financial results for Analysts, Investors, and the Press